Financial results: Bioxyne; Rua Bioscience; Bod Science; Avecho; Wellnex Life; MGC Pharma; Cannasouth by Steve Jones March 7, 2024March 7, 2024 Bioxyne was hit with an impairment charge of A$11.5 million in the first half of FY24 […]
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024November 25, 2024
Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024
BLS launches B2B trading platform CanxChange with $10m sales pipeline in week one by Martin Lane January 22, 2024July 11, 2024
Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023
Company news: Breathe Life Sciences; Cann Group; InhaleRx; X-Hemp; Green Farmers/Elevated Signals by Martin Lane October 19, 2023April 30, 2024
Financial results: Bioxyne/BLS; Emyria; Ecofibre; Zelira Therapeutics by Martin Lane October 3, 2023April 30, 2024
Financial results: Avecho; Wellnex; Zelira; Emyria; Botanix; MGC Pharma; AusCann; Epsilon; Melodiol; Bioxyne by Martin Lane and Steve Jones September 4, 2023April 30, 2024
Bioxyne inks JV to launch AI-powered B2B platform in Australia by Martin Lane August 21, 2023April 30, 2024
ASX-listed Bioxyne launches telehealth platform BLS Clinics by Martin Lane June 21, 2023April 30, 2024
